Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575952 · ClinicalTrials.gov registry record · Phase 1
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
A Phase 1 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT00575952 is a Phase 1 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 27 participants.
The verdict
NCT00575952, a Phase 1 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells.
Interventions
- DRUG Cisplatin
- DRUG Paclitaxel
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Filgrastim
- BIOLOGICAL Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-01-17 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575952
The ClinicalTrials.gov registry entry for NCT00575952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00575952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575952 about?
NCT00575952 is a clinical study titled "Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer". This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and cisplatin...
What is the current status of trial NCT00575952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2008-01-17. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT00575952?
The interventions under investigation include: Cisplatin (DRUG), Paclitaxel (DRUG), Doxorubicin Hydrochloride (DRUG), Filgrastim (BIOLOGICAL), Pegfilgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00575952?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.